Document is current
Any future updates will be listed below
-
Authors
Watts, Justin M.
Wang, Eunice S.
Jonas, Brian A.
Wilson, Florence R.
Park, Julie E.
Cope, Shannon
Sheppard, Aaron
Thomassen, Amber https://orcid.org/0000-0003-2430-0350
de Botton, Stéphane
Cortes, Jorge E. https://orcid.org/0000-0002-8636-1071
-
Funding
Funding for this research was provided by:
Rigel Pharmaceuticals Inc.
- License Information
-
More Information
Article History
Received: 17 December 2025
Accepted: 2 February 2026
First Online: 28 February 2026
Declarations
:
: Aaron Sheppard and Amber Thomassen are employees of Rigel Pharmaceuticals Inc. Florence R. Wilson and Julie E. Park are employees of Precision AQ. Shannon Cope was an employee of Precision AQ at the time the research took place and is now an employee of Unpuzzle Health Economics and Outcomes Research Ltd. Precision AQ, funded by Rigel Pharmaceuticals Inc., performed all analyses and provided professional editorial assistance. Justin M. Watts reports consulting or advisory board roles for BMS, Servier, Rigel, Daiichi Sankyo, Aptose, and Ativarre, research funding from Takeda, Rigel, and Immune Systems Key, Ltd, and is a member of DMC for Rafael Pharma and Reven Pharma. Eunice Wang reports consulting or advisory board roles for J&J, Kite, AmgenStemline, Sumitomo Pharma, Takeda, Pfizer, Rigel, GlaxoSmithKline, Daiichi Sankyo, Blueprint, Jazz, Astellas, Novartis, Gilead, BMS, and Abbvie. Brian A. Jonas reports consulting or advisory board roles for AbbVie, BMS, Daiichi Sankyo, Gilead, Kura, Rigel, Schrodinger, Syndax, and Treadwell, participation in the data monitoring committee for Gilead, and research funding to his institution from AbbVie, Amgen, Aptose, AROG, Biomea, BMS, Celgene, Forma, Forty-Seven, Genentech/Roche, Gilead, GlycoMimetics, Hanmi, Immune-Onc, Jazz, Kymera, Loxo, Pfizer, Pharmacyclics, and Treadwell. Stéphane de Botton reports consulting or advisory board roles for Servier, BMS, GSK, Syndax Pharmaceuticals, Remix Therapeutics, Rigel, Jazz Pharmaceuticals, Astellas, and AbbVie, and research funding from Forma Therapeutics, Auron Therapeutics, BMS, AbbVie, Servier, Jazz Pharmaceuticals, Astellas, and Loxo Oncology. Jorge E. Cortes reports consulting or advisory board roles for Pfizer, Sun Pharma, Syndax, Nerviano, Lilly, Biopath Holdings, Novartis, and Rigel, and research funding from Sun Pharma, AbbVie, Ascentage, and Novartis.
: Results presented in this article are based on a retrospective analysis of data from published studies, and therefore no institutional board review was required. Review boards at participating institutions approved all procedures for the 2102-HEM-101 and AG120-C-001 trials.
